KShotaro Nakamura,1 Toshiro Sugiyama,2 Takayuki Matsumoto,1 Katsunori Iijima,3 Shouko Ono,4 Masahiro Tajika,5 Akira Tari,6 Yasuhiko Kitadai,7 Hiroshi Matsumoto,8.

Slides:



Advertisements
Similar presentations
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Advertisements

Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,
Gastric lymphoma: changing role of surgery
Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Comparative evaluation of conventional methods and Elisa based IgG antibodies detection for diagnosis of helicobacter pylori infection in cases of dyspepsia.
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Casulo C et al. Proc ASH 2013;Abstract 510.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Gastrointestinal Lymphomas.
Dr. CC Chan Kwong Wah Hospital
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
GASTRIC LYMPHOMAS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
ENDOSCOPIC FEATURES IN PATIENTS WITH MARGINAL ZONE LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) IN A FOLLOW UP OF 10 YEARS 1 N.V. Chrysanthos,
How to Critically Appraise A Diagnostic Article Sandy De Groote.
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
LOGO Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-lable, randomised trial 杨 天 Epidemiology.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
JOURNAL REVIEW Questionnaire study and audit of use of ACEI and monitoring in general practice BMJ 1999;318:
Prognose mittels Genexpression Prof. Martin H. Brutsche Kantonsspital St. Gallen-CH.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
EORTC scores of recurrence and progression in a Romanian cohort First author: Anda Ştefan Co-authors: Radu Mihail Boja, PhD Ovidiu Ioan Golea, PhD Ladislau.
Consolidation treatment with Y 90 Ibritumomab Tiuxetan after R-CHOP induction in high-risk patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): a multicentric,
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Institut Bergonié 1 MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN SOFT TISSUE SARCOMA (STS). E. Stoeckle, S. Bonvalot, JY Blay, L. Guillou,
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Hee-Won Kwak, Il Ju Choi, Soo-Jeong Cho, Jong Yeul Lee, Chan Gyoo Kim, Myeong-Cherl Kook, Keun Won Ryu and Young-Woo Kim Journal of Gastroenterology and.
R3 정명화 /Prof. 장재영 Gastrointest. Endosc. 2012; 75:39-46.
Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.
Effect of Helicobacter pylori Eradication on Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasm Am J Gastroenterol 2014; 109:60–67.
1 Motohiko Kato, Tsutomu Nishida, Katsumi Yamamoto, Shiro Hayashi, Shinji Kitamura, Takamasa,Yabuta, Toshiyuki Yoshio, Takeshi Nakamura, Masato Komori,6.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Treatment algorithm – Limited stage Gastric Marginal Zone Lymphoma Diagnosis: – Histology including appropriate B-cell immunohistochemical panel and staining.
Helicobacter pylori and Gastric Lymphoma
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
Eradication of Helicobacter pylori After Endoscopic Resection of Gastric Tumors Does Not Reduce Incidence of Metachronous Gastric Carcinoma Clinical Gastroenterology.
Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia: an analysis using the Vienna classification R1 김진숙 / Prof. 장재영.
Should Elderly Patients Undergo Additional Surgery After Non-Curative Endoscopic Resection for Early Gastric Cancer? Long-Term Comparative Outcomes R3.
Clinical Practice Helicobacter pylori Infection Kenneth E.L. McColl, M.D. N Engl J Med Volume 362(17): April 29, 2010.
P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.
BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.
Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status : prospective endoscopic cohort.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
R3 김재민 / Prof. 장영운 Journal conference 1.
Helicobacter pylori eradication prior bariatric/metabolic surgery
Reeder CB et al. ASCO 2009; Abstract (Poster)
Lymphoma NICE guidelines July 2016
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Response to chemotherapy
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
Institute of Oncology “Ion Chiricuță”, Cluj, Romania
Kahl BS et al. Proc ASH 2011;Abstract LBA-6.
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori  Stephan Timm, Marco Sailer, Karl–hermann.
CTCL: INNOVATIVE TREATMENTS GEMCITABINE
Volume 4, Pages (October 2018)
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
Role for XRT in treatment of early stage Follicular lymphoma?
Lymphoma in Pediatrics 23rd Nov 2018
Treatment of Stage III Non-small Cell Lung Cancer
Surgical resection of metachronous liver metastases
Presentation transcript:

KShotaro Nakamura,1 Toshiro Sugiyama,2 Takayuki Matsumoto,1 Katsunori Iijima,3 Shouko Ono,4 Masahiro Tajika,5 Akira Tari,6 Yasuhiko Kitadai,7 Hiroshi Matsumoto,8 Tadanobu Nagaya,9 Toshiro Kamoshida,10 Norihiko Watanabe,11 Toshimi Chiba,12 Hideki Origasa,13 Masahiro Asaka,14 for the JAPAN GAST Study Group Gut 2012;61: Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori : a multicentre cohort follow up study of 420 patients in Japan R2 Jin suk Kim / Prof. Young woon Chang

Introduction Gastric MALT lymphoma : 40-50% of primary gastric lymphomas : 20-40% of extranodal lymphomas : 4-9% of all malignant lymphomas : 1-6% of all gastric malignancies H.pylori Gastric MALT lymphoma Causative role Complete remission (CR) of lymphoma Lead to H.pylori X

Introduction H.pylori eradication : Regarded as the 1 st -line Tx. of gastric MALT lymphoma Large scale long-term F/U after eradication : Limited with regard to relapse or progression and survival To elucidate the long-term clinical outcome of Helicobacter pylori eradication therapy

Methods - Study design - Japanese multicentre cohort follow-up study - Patients with primary gastric MALT lymphoma diagnosed and treated by H.pylori eradication between March March 2007 Inclusion criteria - Presence of gastric MALT lmyphoma ( according to the WHO classification and compatible with Wotherspoon’s histological score of 4 or 5 in the pretreatment gastric biopsy specimens) - H.pylori eradication using PPI + combination of two antibiotics as the 1 st line treatment - F/U period of at least 3yrs after successful eradication therapy Exclusion criteria - Primary MALT lymphoma arising in the extragastric organs - Presence of DLBCL prior to the H pylori eradication - Positive H. pylori infection after the final eradication therapy

Methods - Subjects patients, 21 institutes - H.pylori status : Histology, culture, rapid urease test, C urea breath test - H.pylori infection : Positive  one or more of the test showed positive result : Negative  all test showed negative result - Endoscopy type : Superficial, Ulcerative Polypoid or others

Methods - Subjects - Clinical stage : Basis of the Lugano staging system (modification of the Ann-Arbor classification) - EUS : Perfomed to evaluate the depth of invasion & dgree of perigastric lymphadenopathy

Methods - Assessment after H.pylori eradication therapy -Bx. Specimens (the GELA histological grading system) - Complete histological response (ChR) - Probable minimal residual disease (pMRD) - Responding residual disease (rRD) - No change (NC) - Follow up endoscopy with Bx. : Every 3-6months until confirmation of ChR/pMRD - Treatment failure : Relapse after ChR/pMRD or Progressive disease Responders Non-Responders

Methods - Second line treatments for non- responders - Patients with treatment failure or persistence of lymphoma (1) Watch and wait strategy : No treatment (2) Various antineoplastic treatments : Radiotherapy, chemotherapy with or without rituximab, chemoradiotherapy, rituximab alone, surgical resection or others

Methods - Prognostic factors and statistical analysis Supplemental table A Clinicopathologic characteristics of 420 patients with gastric MALT lymphoma

Results - Response to H.pylori eradication Table 1. Association between Clinicopathological factors & response to the H pylori eradication

Results - Response to H.pylori eradication Table 2. Predictive factors for resistance to Helicobacter pylori eradication therapy as determined by logistic regression analysis

Results - Response in responders Figure 1. Clinical course of the 420 study patients 77 % 23% 1 patient : Surgical resection 6 patients: CTx. or RTx. Re-eradication of H.pylori spontaneousl y achieved ChR again

Results - Treatments for non-responders Figure 1. Clinical course of the 420 study patients. 77 % 23% Lung meta. CTx, RTx, Surgical resection  PR Antibiotics CTx, RTx, Surgical resection

Results - Treatment failure, long term outcome and prognostic factors Figure 2. KaplaneMeier curves of 420 patients with gastric MALT lymphoma after H.pylori eradication FFT F 92%90% 80% OS 99%95% 91%

Results - Treatment failure, long term outcome and prognostic factors Figure 2. KaplaneMeier curves of 420 patients with gastric MALT lymphoma after H.pylori eradication EFS 92%86% 76%

Conclusion The excellent long-term outcome of gastric MALT lymphoma after H pylori eradication was confirmed by this large-scale follow-up study.